Diabetes drug shows potential to slow prostate cancer cell growth (Actos)

An international team of scientists has identified similarities in the mechanisms of diabetes and cancer: as the researchers show, the protein PPARγ, which is central to the regulation of metabolic processes, can also influence the growth of prostate cancer cells. PPARγ is already known to be a target of certain drugs used to treat type 2 diabetes. The results of the study indicate that such drugs could also represent a promising approach for the treatment of prostate cancer. PPARγ has been known in diabetes research for quite some time, as it has an influence on insulin sensitivity. For more than...